These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 1342585)

  • 1. Anti-HIV antibodies: the source of specificity.
    Vaz NM
    Braz J Med Biol Res; 1992; 25(11):1059-61. PubMed ID: 1342585
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-F(ab')2 antibody in HIV type 1 infection: relationship to hypergammaglobulinemia and to antibody specific to the V3 loop region of glycoprotein 120.
    Morrison SA; Pearson SL; Steigbigel RT
    AIDS Res Hum Retroviruses; 1998 Apr; 14(6):491-8. PubMed ID: 9566551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AIDS and Trojan horses.
    Elder D; Harris R
    Riv Biol; 1992; 85(2):247-8. PubMed ID: 1361074
    [No Abstract]   [Full Text] [Related]  

  • 4. Unusually strong, but transient, nonspecific human immunodeficiency virus types 1 and 2 antibody reactivity.
    Kiely P; Miller K; Denham-Ricks P; Kebede M
    Transfusion; 2008 Jul; 48(7):1521-2. PubMed ID: 18651910
    [No Abstract]   [Full Text] [Related]  

  • 5. [Affinity of anti-HIV antibodies in patients with asymptomatic and symptomatic HIV infection].
    Radkowski M; Laskus T; Goch A; Babiuch L; Slusarczyk J
    Przegl Epidemiol; 1991; 45(4):369-72. PubMed ID: 1841418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunology. Close to the edge: neutralizing the HIV-1 envelope.
    Nabel GJ
    Science; 2005 Jun; 308(5730):1878-9. PubMed ID: 15976295
    [No Abstract]   [Full Text] [Related]  

  • 7. Specificities of HIV-1 antibodies in serum and in peripheral blood supernatants.
    Vendrell JP; Ducos J; Rabesandratana H; Reynes J; Huguet MF; Cannat A; Serre A
    Lancet; 1989 Mar; 1(8636):501. PubMed ID: 2563873
    [No Abstract]   [Full Text] [Related]  

  • 8. Rapid development of AIDS in an HIV-1-antibody-negative homosexual man.
    Martin-Rico P; Pedersen C; Skinhøj P; Nielsen C; Lindhardt BO
    AIDS; 1995 Jan; 9(1):95-6. PubMed ID: 7893450
    [No Abstract]   [Full Text] [Related]  

  • 9. Antibodies to an HIV-1 synthetic peptide with partial homology to MULV P15E do not protect against AIDS.
    Lange J; Vahlne A; Dekker J; de Wolf F; Goudsmit J
    AIDS; 1989 Jun; 3(6):402-3. PubMed ID: 2502156
    [No Abstract]   [Full Text] [Related]  

  • 10. Autoimmune phenomena and activation of the immune system in HIV infection.
    Radkowski M; Kaminska E; Laskus T
    Infection; 1996; 24(1):56. PubMed ID: 8852469
    [No Abstract]   [Full Text] [Related]  

  • 11. Specificity of chimpanzee antibodies binding a strain-specific HIV-1 neutralization epitope of the external envelope.
    Goudsmit J; Bakker M; Smit L; Meloen RH
    J Med Primatol; 1989; 18(3-4):357-62. PubMed ID: 2474656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New tests produced by Organon Teknika for the diagnosis of antibodies to HIV-1 and HIV-2.
    Chantrain C
    Przegl Epidemiol; 1992; 46(1-2):3-10. PubMed ID: 1475387
    [No Abstract]   [Full Text] [Related]  

  • 13. Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization.
    Spear GT; Takefman DM; Sharpe S; Ghassemi M; Zolla-Pazner S
    Virology; 1994 Nov; 204(2):609-15. PubMed ID: 7941328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Negative results of a rapid antibody test for HIV in a 16-month-old infant with AIDS.
    Zhang Y; Wang J; Wilson GJ; Tang YW; Lu HZ
    Ann Clin Lab Sci; 2008; 38(3):293-5. PubMed ID: 18715861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reactivities of HIV-1 gag-derived peptides with antibodies of HIV-1-infected and uninfected humans.
    Haist S; März J; Wolf H; Modrow S
    AIDS Res Hum Retroviruses; 1992 Nov; 8(11):1909-17. PubMed ID: 1489579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Status of HIV vaccine development.
    Minor JR
    Am J Hosp Pharm; 1994 Jul; 51(14):1816-8. PubMed ID: 7942913
    [No Abstract]   [Full Text] [Related]  

  • 17. Urgently needed: a filter for the HIV-1 vaccine pipeline.
    Moore JP; Burton DR
    Nat Med; 2004 Aug; 10(8):769-71. PubMed ID: 15286768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The prospects for using immunoadsorption in AIDS therapy].
    Shmatkov BA; Kulaev DV
    Zh Mikrobiol Epidemiol Immunobiol; 1991 May; (5):24-7. PubMed ID: 1882622
    [No Abstract]   [Full Text] [Related]  

  • 19. The chemistry of site-directed serology for HIV infections.
    Norrby E; Biberfeld G; Johnson PR; Parks DE; Houghten RA; Lerner RA
    AIDS Res Hum Retroviruses; 1989 Oct; 5(5):487-93. PubMed ID: 2480152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible beneficial effects of neutralizing antibodies and antibody-dependent, cell-mediated cytotoxicity in human immunodeficiency virus infection.
    Sawyer LA; Katzenstein DA; Hendry RM; Boone EJ; Vujcic LK; Williams CC; Zeger SL; Saah AJ; Rinaldo CR; Phair JP
    AIDS Res Hum Retroviruses; 1990 Mar; 6(3):341-56. PubMed ID: 1971182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.